A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer.

Y, Hirooka; A, Itoh; H, Kawashima; K, Hara; K, Nonogaki; T, Kasugai; E, Ohno; T, Ishikawa; H, Matsubara; M, Ishigami; Y, Katano; N, Ohmiya; Y, Niwa; K, Yamamoto; T, Kaneko; M, Nieda; K, Yokokawa; H, Goto

doi:10.1097/mpa.0b013e318197a9e3

Public

A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer.

Shared by NobleBlocks on Apr 1, 2009 • 12:00 AM UTC

Authors:

Hirooka Y

Itoh A

Kawashima H

Abstract

<h4>Objectives</h4>Dendritic cell (DC) therapy frequently induces a measurable immune response. However clinical responses are seen in a minority of patients, presumably due to insufficient expansion of antigen-specific cytotoxic T lymphocytes (CTLs) capable of eradicating tumor cells. To increase t...

Discussions